Diversify to multiply

Article Abstract:

Investing in biotech is to dream of a better future for patients and of sharing in the profits. However, biotech investors can suffer two main night-mares apart from management misconduct, of which the first occurs when a new company's only near-term product suffers a clinical or regulatory setback, the second arises when a company takes a promising drug through approval and marketing.

Management dynamics, Management, Company business management, Pharmaceutical biotechnology

---

A special biotech speculation

Article Abstract:

The Canada-based Oncology Company YM Biosciences makes three biotech products, which are aimed to acquire potential markets. The three biotech products include tesmilifene, AeroLEF (aerosolized liposome-encapsulated fentanyl) and TheraCIM h-R3 (nimotuzumab).

Marketing procedures, Finance, Marketing, Company marketing practices, Company financing, Fentanyl

---

Splurge or merge?

Article Abstract:

The wisdom of merging, corporate investment and shareholder dividends for biotechnology companies is discussed.

Column

Similar abstracts:

• Abstracts: Charitable contributions: special deductions available to corporations
• Abstracts: Charitable contributions: special deductions available to corporations. part 2 Loss disallowance post-Rite Aid: the IRS and treasury revisit the treatment of subsidiary stock losses
• Abstracts: Investors' assessment of implicit environmental liabilities: an empirical investigation. Environmental reporting management: a continental European perspective
• Abstracts: Rep. Lewis rejects Va. class multi-year buy, wary on JSF. Naval research unveil tiny atomic clock
• Abstracts: Everything under control: A child's eye view of advertising. Children's understanding of television advertising intent

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.